Abstract
e15190 Background: Octreotide LAR is indicated by the FDA for severe diarrhea/flushing episodes associated with metastatic carcinoid tumors and recommended in NCCN guidelines for tumor control and ...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
